Nucleus Biologics

Nucleus Biologics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11M

Overview

Nucleus Biologics is a specialized service and product provider supporting the advanced therapy medicinal product (ATMP) industry, particularly cell and gene therapy developers. The company focuses on the formulation, development, and supply of custom cell culture media and process liquids, which are critical yet complex components in biomanufacturing. By offering tailored solutions and acting as a strategic partner, Nucleus Biologics helps clients reduce development timelines and mitigate supply chain risks. Its business model is centered on providing essential services and consumables to therapeutic developers rather than developing its own drug pipeline.

Cell TherapyRegenerative Medicine

Technology Platform

Custom cell culture media formulation and development platform, including analytical testing, dual-supply chain management, and fill-finish services for GMP manufacturing.

Funding History

2
Total raised:$11M
Series A$8.5M
Seed$2.5M

Opportunities

The rapid growth of the cell and gene therapy market creates massive demand for specialized, reliable cell culture media.
The industry shift towards defined, xeno-free formulations and the need to de-risk supply chains present a strong value proposition for Nucleus Biologics' customized service model.

Risk Factors

High dependency on the success and funding climate of the broader cell therapy sector.
Intense competition from large, diversified life science reagent companies.
Vulnerabilities in the complex global supply chain for raw materials.

Competitive Landscape

Nucleus Biologics competes with large, integrated life science tools companies (e.g., Thermo Fisher, Sartorius) that offer off-the-shelf media, as well as other specialized media formulation boutiques. Its differentiation lies in deep customization, client partnership, and a focus on mitigating supply chain risk for critical GMP materials.